MedPath
HSA Product

OXYCONTIN 20mg prolonged release tablets

Product approved by Health Sciences Authority (SG)

Basic Information

OXYCONTIN 20mg prolonged release tablets

TABLET, FILM COATED, EXTENDED RELEASE

Regulatory Information

SIN13078P

April 7, 2005

Prescription Only

Therapeutic

ORAL

August 10, 2023

May 30, 2025

XN02AA05

Company Information

MUNDIPHARMA PHARMACEUTICALS PTE. LTD.

MUNDIPHARMA PHARMACEUTICALS PTE. LTD.

Active Ingredients

Detailed Information

Contraindications

**Contraindications** Hypersensitivity to opioids and to any of the constituents or in any situation where opioids are contraindicated, acute respiratory depression , cor pulmonale, cardiac arrhythmias, severe bronchial asthma, chronic obstructive airways disease, , elevated carbon dioxide levels in the blood, paralytic ileus, suspected surgical abdomen, acute abdomen, severe constipation, moderate to severe hepatic impairment, severe renal impairment (creatinine clearance < 10ml/min) ,delayed gastric emptying, acute alcoholism, brain tumor, increased cerebrospinal or intracranial pressure, head injury, severe CNS depression, convulsive disorders, delirium tremens, hypercarbia, concurrent administration of monoamine oxidase inhibitors or within 2 weeks of discontinuation of their use. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Not recommended for pre-operative use or for the first 24 hours post-operatively. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Indication Information

**Indication** The management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

© Copyright 2025. All Rights Reserved by MedPath